A Long Survival of a Secondary Acute Myeloid Leukemia Patient under Low-dose Cytosine Arabinoside and Valproic Acid
نویسنده
چکیده
The prognosis of elderly patients with acute myeloid leukemia is poor, especially when they have associated diseases that affect their performance status. Azacitidine, decitabine, and low-dose cytosine arabinoside are drugs of choice for the treatment of unfit patients with acute myeloid leukemia. Their combination with other adjuvant drugs worth to be studied, in order to increase the therapeutic effectiveness. We present a female patient who was treated with low-dose cytosine arabinoside and valproic acid. She is alive at 30 months since the diagnosis of acute myeloid leukemia.
منابع مشابه
A Case of Acute Myeloid Leukemia Caused by Low Dose Methotrexate Used to Treat a Rheumatoid Arthritis Patient
Methotrexate is an anti-rheumatic agent used as a first-line tretment for rheumatoid arthritis. Hematological malignancies like lymphoma or acute myeloid leukemia have been reported to be secondary to treatment with Methotrexate, but are very uncommon. We report here the first Moroccan case of RA patient on low dose MTX, who developed AML. We also reviewed all similar cases.
متن کاملPost-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
INTRODUCTION Modern therapy makes it possible for 60-80% patients with acute myeloid leukemia to achieve complete remission after induction therapy. However, most of them will relapse within six months to a year without additional cytostatic therapy. The questions regarding post-remission therapy remain unanswered. The objective of this study was to compare the survival and relapse rate among t...
متن کاملHigh Dose Cytarabine-Induced Peripheral Neuropathy in a Patient with Acute Myelocytic Leukemia
High dose (1-3 g/m2 every 12 hours) cytosine arabinoside (ara-C) is a potent treatment for acute myeloid leukemia (AML) in consolidation therapy which is well known that improves the diseasefree-survival (DFS). Cerebellar neurotoxicity is well-recognized complication following high-dose cytosine arabinoside (≥3 g/m2 every 12 hours), but peripheral neurotoxicity is not common as well. This poten...
متن کاملTreatment of early acute nonlymphatic leukemia with low dose cytosine arabinoside.
Successful induction of remISSIons in adults with acute nonlymphatic leukemia (ANLL) requires the use of high dose aggressive chemotherapy which is not weIl tolerated by older adults and few remissions are obtained in patients with ANLL secondary to refractory anemia and other dis orders (Moloney and Rosenthai, to be published) For years investigators have attempted to discover methods of produ...
متن کاملGM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Priming of leukemic cells with cytokines may enhance the efficacy of cell-cycle chemotherapy. In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). In a single-instit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2016